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Angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 have been implicated in cell
entry for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for
coronavirus disease 2019 (COVID-19). The expression of ACE2 and TMPRSS2 in the lung
epithelium might have implications for the risk of SARS-CoV-2 infection and severity of COVID-19.
We use human genetic variants that proxy angiotensin-converting enzyme (ACE) inhibitor drug
effects and cardiovascular risk factors to investigate whether these exposures affect lung ACE2 and
TMPRSS2 gene expression and circulating ACE2 levels. We observed no consistent evidence of an
association of genetically predicted serum ACE levels with any of our outcomes. There was weak
evidence for an association of genetically predicted serum ACE levels with ACE2 gene expression
in the Lung eQTL Consortium ( p = 0.014), but this finding did not replicate. There was evidence of
a positive association of genetic liability to type 2 diabetes mellitus with lung ACE2 gene
expression in the Gene-Tissue Expression (GTEx) study ( p = 4 × 10−4) and with circulating plasma
ACE2 levels in the INTERVAL study ( p = 0.03), but not with lung ACE2 expression in the Lung
eQTL Consortium study ( p = 0.68). There were no associations of genetically proxied liability to the
other cardiometabolic traits with any outcome. This study does not provide consistent evidence to
support an effect of serum ACE levels (as a proxy for ACE inhibitors) or cardiometabolic risk
factors on lung ACE2 and TMPRSS2 expression or plasma ACE2 levels.1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus
disease 2019 (COVID-19) pandemic [1]. Serine protease TMPRSS2 is involved in priming the SARS-CoV-
2 spike protein for cellular entry through the angiotensin-converting enzyme 2 (ACE2) receptor [2–5].
COVID-19 patients most frequently present with respiratory tract infection symptoms [6–11]. It follows
that the expression of ACE2 and TMPRSS2 in the lung epithelium might have implications for the risk
of SARS-CoV-2 infection and severity of COVID-19 [2,12,13].
Emerging evidence suggests that patients with underlying cardiometabolic risk factors and airway
disease are more likely to suffer from severe COVID-19 [6–11]. It has been speculated that the angiotensin-
converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) classes of antihypertensive




3the expression of ACE2 and thus affect susceptibility to SARS-CoV-2 infection and severity of consequent
COVID-19 [14–20]. Although ACE and ACE2 are both dipeptidyl carboxydipeptidases, they have distinct
physiological effects. ACE cleaves angiotensin I to angiotensin II, which consequently activates the
angiotensin II receptor type 1 pathway resulting in vasoconstriction and inflammation. By contrast, ACE2
degrades angiotensin II to angiotensin 1–7 and angiotensin I to angiotensin 1–9. Angiotensin 1–9 activates
the Mas receptor to have vasodilatory and anti-inflammatory effects. Animal studies have supported
effects of ACEi and ARB drugs on ACE2 expression and activity [21–28], with mixed findings for
associations of ACEi and ARB drug use with ACE2 activity and levels in human tissues also reported
[29–31]. It is important that any causal effects of these medications and cardiometabolic traits on ACE2
expression be further investigated. Identification of a mechanistic basis by which such exposures affect the
risk and severity of COVID-19 could provide useful insight for disease prevention and treatment. This
could be used to inform optimal medication use and strategies for shielding vulnerable individuals, as
well as improving the evidence base for public health campaigns.
The Mendelian randomization approach uses genetic variants related to exposure as instrumental
variables for investigating the effect of that exposure on an outcome [32]. Genetic variants are treated
analogously to treatment allocation in a randomized controlled trial. Typically, molecular
measurements such as gene expression or circulating protein levels are regarded in Mendelian
randomization investigations as exposure variables. Here, following the work of Rao et al. [33], we
treat these molecular measurements as the outcomes in our investigation. The aim of this study was
to apply Mendelian randomization to investigate whether ACE2 and TMPRSS2 gene expression in the
lung and circulating levels of ACE2 in the plasma are associated with (i) genetic variants in the ACE
gene region that can be considered as proxies for the effect of ACEi drugs and (ii) genetic variants
related to cardiometabolic risk factors. We also use publicly available data on genetic associations
with COVID-19 susceptibility to investigate whether genetically predicted serum ACE levels are
associated with risk of hospitalization due to COVID-19.2. Methods
2.1. Genetic associations with exposure variables
Two different genetic instruments that proxy ACEi drug effects were considered. First, we selected 17 single-
nucleotide polymorphisms (SNPs) in the ACE locus that were associated with serum ACE concentration in
the Outcome Reduction with Initial Glargine INtervention (ORIGIN) trial and did not have strong pairwise
correlation (r2 < 0.1) [34]. Accounting for correlation, these variants explain 29.0% of the variance in serum
ACE concentration, corresponding to an F statistic of 85.4 (INTERVAL), 17.7 (Lung eQTL Consortium)
and 8.8 (GTEx). Second, we selected a single SNP, rs4291, located at the ACE locus that was associated
with systolic blood pressure (SBP) at p = 9 × 10−20 in a study of 757 601 European-ancestry individuals
[35,36]. Each blood pressure-lowering allele of this SNP was associated with a 0.28 mmHg reduction in
SBP [35]. This variant explains <0.1% of the variance in blood pressure. There were no other SNPs at this
locus that were associated with SBP at a genome-wide level of significance (p < 5 × 10−8) and did not have
strong pairwise correlation (r2 < 0.1) with the index variant [35]. To assess the validity of the serum ACE
variants, we assessed their associations with SBP in the UK Biobank study [37].
We further considered six cardiometabolic traits as exposure variables: body mass index (BMI), chronic
obstructive pulmonary disease (COPD), lifetime smoking index, low-density lipoprotein cholesterol
(LDL-C), SBP and type 2 diabetes mellitus (T2DM). These traits were chosen as they have been associated
with prognosis of COVID-19 [6–11]. Genetic association estimates for these exposures were obtained from
the publicly available genome-wide association study (GWAS) summary data sources listed in table 1.
Genetic variants selected as instruments were SNPs associated with the corresponding trait at a genome-
wide level of statistical significance (p < 5 × 10−8) and were uncorrelated (r2 < 0.001). Clumping of
correlated variants was performed using the TwoSampleMR package in R [43].
2.2. Genetic associations with outcome variables
Genetic associations with the expression of ACE2 and TMPRSS2 in lung tissue were obtained from two
sources: (i) the Gene-Tissue Expression (GTEx) project [44] and (ii) the Lung eQTL (expression
quantitative trait loci) Consortium [45]. Genetic associations with risk of hospitalization due to
COVID-19 were obtained from release 4 (alpha version) of the COVID-19 Host Genomics Initiative [46].


















lifetime smoking index 462 690 European 126 0.36 [40]
low-density lipoprotein
cholesterol (LDL-C)
188 577 European 80 7.9 [41]
systolic blood pressure
(SBP)
318 417 British 192 2.9 [37]
type 2 diabetes
mellitus (T2DM)
74 124 cases and
824 006
controls





GTEx genetic association estimates were obtained in 515 individuals of predominantly European (85%)
ancestry. RNAsequencingwas performedusing the Illumina TruSeqTMRNAsample preparation protocol,
and gene-level expression quantification was performed using RNA-SeQC for gene-level read counts and
transcripts per million values [47]. Whole-genome sequencing was performed by the Broad Institute’s
Genomics Platform and only common variants (minor allele frequency >0.05) were retained. Genome-
wide eQTL analysis was performed for the expression of ACE2 and TMPRSS2 in primary tissue samples
taken from the lung. Genetic associations with imputed variants across the autosomal chromosomes were
adjusted for five principal components from the genotype data, 60 probabilistic estimations of expression
residuals factors [48], sequencing platform (Illumina HiSeq 2000 or HiSeq X), sequencing protocol
(polymerase chain reaction-based or free) and sex. For each gene, expression values between samples
were normalized using the trimmed means of M-values method in EdgeR [49]. Expression values were
normalized across samples using an inverse-normal transformation.
Lung eQTL Consortium genetic association estimates were obtained in 1038 individuals of European
ancestry [45]. Tissue samples were obtained at three different institutions: University of British Columbia,
Laval University and University of Groningen. Genome-wide eQTL analysis was performed for the
expression of ACE2 using a probe set 100134205_TGI_at and two probe sets for TMPRSS2,
100130004_TGI_at and 100157336_TGI_at (subsequently referred to as 1 and 2). Expression profiling was
performed using an Affymetrix custom array (see Gene Expression Omnibus platform GPL10379) [45].
The probe sets measure different transcripts, and the specific probes for each probe set are detailed in
electronic supplementary material, table S1. Expression levels were much higher for the first probe set, and
so these results are more reliable. All participants were genotyped using the Illumina Human 1 M Duo
BeadChip and the genotypes were imputed using the Haplotype Reference Consortium reference panel.
Expression values were first standardized for age, sex and smoking status using robust linear regression.
Genetic associations were estimated in each cohort separately using a linear additive genetic model. The
estimates were combined across cohorts using an inverse-variance weighted model with fixed effects.
Genetic association estimates with circulating plasma ACE2 levels were obtained in a subcohort of
4998 blood donors enrolled in the INTERVAL BioResource [50]. Plasma ACE2 levels were measured
using a multiplex proximity extension immunoassay (Cardiovascular 2 panel, Olink Bioscience,
Uppsala, Sweden). A total of 4947 samples passed quality control. The data were pre-processed using
standard Olink workflows including applying median centring normalization across plates, where the
median is centred to the overall median for all plates, followed by log2 transformation to provide
normalized protein levels (NPX). NPX values were regressed on age, sex, plate, time from blood draw
to processing (in days) and season. The residuals were then rank-inverse normalized. Genotype data
were processed as described previously [51]. Genome-wide pQTL analysis was performed by linear
regression of the rank-inverse normalized residuals on genotype in SNPTEST [52], with the first three




5Genetic association estimates with hospitalization due to COVID-19 were obtained from version 4
(release alpha) of the COVID-19 Host Genomics Initiative, which included 6492 cases and 1 012 809
controls from the general population from 17 studies, mostly from participants of European ancestries
[46]. Association estimates were obtained within each study with adjustment for age, age-squared, sex,
at least 20 principal components and technical covariates, and then meta-analysed across studies.
2.3. Mendelian randomization analyses
For the analysis investigating genetically proxied ACEi drug effects using the rs4291 variant, we report
the genetic associations with lung ACE2 and TMPRSS2 expression, plasma ACE2 levels and risk of
COVID-19 hospitalization per blood pressure-lowering allele.
For all other Mendelian randomization analyses, estimates were obtained from the inverse-variance
weighted method under a random-effects model [53]. For the polygenic analyses based on the ACE gene
locus, we accounted for the correlation between variants using generalized weighted regression [54].
Heterogeneity between Mendelian randomization estimates from different genetic variants for the
same exposure trait was expressed using the I2 statistic [55]. For any identified associations at p < 0.05,
the weighted median [56], MR-Egger [57] and contamination-mixture methods [58], which are more
robust to the inclusion of pleiotropic variants, were performed as sensitivity analyses.
Mendelian randomization estimates represent the change in the outcome per one standard deviation
increase in genetically predicted levels of the exposure for continuous exposure traits and per unit
increase in the loge odds of the exposure for binary traits. All outcome measures were rank-based
inverse-normal transformed, and so changes in the outcome measures are in standard deviation units,
with the exception of COVID-19 hospitalization, for which estimates represent odds ratios.
2.4. Ethical approval, data availability and reporting
The data used in this work are obtained from published studies that obtained relevant participant consent
and ethical approval. All variants used as instruments and their genetic association estimates were selected
from publicly available data sources, and are provided in electronic supplementary material, tables S2–S9.
GWAS summary data for all the outcomes considered in this study are publicly available at http://dx.doi.
org/10.6084/m9.figshare.12102681 (GTEx), http://dx.doi.org/10.6084/m9.figshare.12102711 (Lung eQTL
Consortium), and http://dx.doi.org/10.6084/m9.figshare.12102777 (INTERVAL). The results from the
analyses performed in this work are presented in the main manuscript or its supplementary files. This
paper has been reported based on recommendations by the STROBE-MR Guidelines (Research Checklist)
[59]. The study protocol and details were not pre-registered.3. Results
Results for the analyses investigating genetically proxiedACEi drug effects are displayed in figure 1. Genetic
associations of the variants with serumACE levels, SBP and the molecular outcomemeasures are plotted in
electronic supplementary material, figure S1. The variants were associated with SBP in the expected
direction: 0.22 mmHg (95% confidence interval 0.06 to 0.37, p = 0.006) increase per one standard
deviation increase in ACE. There was evidence of an association with ACE2 expression in the Lung eQTL
Consortium for the variants associated with serum ACE: -0.087 standard deviation change (95%
confidence interval -0.156 to -0.018, p = 0.014) in ACE2 expression per one standard deviation increase in
serum ACE. For the other molecular outcome measures, there was no evidence of associations
considering the variants associated with serum ACE (figure 1a), or the variant associated with SBP
(figure 1b). Results were similar in sensitivity analyses restricted to 12 variants associated with serum
ACE at a genome-wide level of significance ( p < 5 × 10−8) and for the lead variant (rs4343) only
(electronic supplementary material, figure S2). There was no evidence of the association between
genetically predicted serum ACE and risk of hospitalization due to COVID-19 for the 17 variants (odds
ratio 1.02 per standard deviation increase in ACE; 95% confidence interval 0.94 to 1.10) or for the SBP
variant (odds ratio 1.05 per blood pressure decreasing allele; 95% confidence interval 0.99 to 1.12).
The main inverse-variance weighted method Mendelian randomization results for the
cardiometabolic risk factors are displayed in figure 2 for lung ACE2 expression and plasma ACE2
concentrations, and in figure 3 for lung TMPRSS2 expression. There was evidence of a positive
association of genetic liability to T2DM with lung ACE2 gene expression in GTEx ( p = 4 × 10−4) and
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Figure 1. Genetic associations with ACE2 and TMPRSS2 gene expression in the lung (GTEx and Lung eQTL Consortium) and circulating
ACE2 protein levels in the plasma (INTERVAL): (a) per one standard deviation increased ACE concentration conferred through variants at
the ACE gene and (b) per blood pressure-lowering allele for the rs4291 variant in the ACE gene (bottom panel). The two sets of results





with circulating plasma ACE2 levels in INTERVAL ( p = 0.03) (electronic supplementary material, figure
S3). Similar point estimates were obtained when performing the weighted median, MR-Egger and
contamination-mixture Mendelian randomization sensitivity analyses that are more robust to the
presence of pleiotropic variants, although the confidence intervals were wider (electronic
supplementary material, table S10). The MR-Egger method did not identify any evidence of
directional pleiotropy biasing the analysis (electronic supplementary material, table S10). There was
no evidence of an association of genetic liability to T2DM with lung ACE2 gene expression in the
Lung eQTL Consortium ( p = 0.68). There was no evidence of an association between genetically
predicted levels of any of the other cardiometabolic traits with ACE2 or TMPRSS2 gene expression in
GTEx or the Lung eQTL Consortium, or with circulating plasma ACE2 levels in INTERVAL.4. Discussion
In the current COVID-19 pandemic, there is an urgent need to elucidate mechanisms underlying risk
and severity of COVID-19, with a view to informing preventative and therapeutic strategies. In this
study, we used human genetic variants that proxy ACEi drug effects and cardiometabolic risk factors
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Figure 2. Mendelian randomization estimates for the change in ACE2 gene expression in the lung (GTEx and Lung eQTL Consortium)
and circulating ACE2 protein levels in the plasma (INTERVAL) per unit increase in genetically predicted levels of the exposure.
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Figure 3. Mendelian randomization estimates for the change in TMPRSS2 gene expression in the lung per unit increase in
genetically predicted levels of the exposure. The two sets of results for the Lung eQTL Consortium refer to two separate probe





We did not find a consistent association of genetically predicted serum ACE levels with lung ACE2
and TMPRSS2 expression or with circulating plasma levels of ACE2. In one dataset, we found evidence
that increased serum ACE may lead to decreased expression of ACE2, meaning that ACE inhibition
would increase ACE2 expression. However, this finding did not replicate. Additionally, genetically
predicted serum ACE levels were not associated with risk of hospitalization due to COVID-19.
Previously identified changes in ACE2 expression in human tissues following ACEi treatment may not




8professional bodies for supporting the continuation of ACEi and ARB antihypertensive drugs in patients
with COVID-19 unless there is a clinical justification for stopping [60,61]. Indeed, appropriate use of these
medications is of proven benefit [62,63], and their abrupt interruption can also do considerable harm
[64,65]. While there has also been speculation that ACEi and ARB antihypertensive drugs might
reduce the severity of COVID-19 [19,66–68], with clinical trials to explore this currently planned [60],
our findings are also consistent with guidance that patients should not start taking these drug classes
unless clinically indicated [60].
Our results identified inconsistent support for an effect of liability to T2DM on lung ACE2 expression
and plasma ACE2 levels. An association of genetic liability to T2DM with lung ACE2 expression in the
GTEx project has previously been described [33]. However, we identified no association of genetic
liability to T2DM with lung ACE2 expression in the Lung eQTL Consortium. This discrepancy may be
attributable to the different populations considered in the GTEx project and the Lung eQTL
Consortium [44,45]. While the Lung eQTL Consortium considered lung tissue from patients requiring
resectional surgery, all samples in the GTEx project were taken from healthy tissue in deceased donors
[44,45]. Taken together, our results do not provide consistent support for an effect of cardiometabolic
traits on lung ACE2 or TMPRSS2 expression or plasma ACE2 levels. While the association between
cardiometabolic traits and severity of COVID-19 could be attributable to alternative mechanisms [6–
11], these risk factors can still be used to stratify patients in terms of their vulnerability. Similarly,
while our current findings do not support a causal effect of COPD or smoking on lung ACE2
expression, these factors may still be used to inform risk models for severe COVID-19 [69].
Since the initial submission of this manuscript, further data have become available on genetic
associations with susceptibility to COVID-19 [46,70]. Mendelian randomization analyses have supported
the effect of higher BMI and lifetime smoking on increasing susceptibility to severe COVID-19 [71]. The
discrepancy with our current findings, which did not identify an association of genetically predicted BMI
or smoking with lung ACE2 and TMPRSS2 expression or with circulating plasma levels of ACE2 may be
explained by effects of these risk factors on susceptibility to severe COVID-19 through mechanisms
unrelated to lung ACE2 or TMPRSS2 gene expression or plasma ACE2 protein expression.
Our study has a number of strengths. We used genetic variants as instrumental variables for studying
the effect of ACEi drugs and cardiometabolic risk factors and were therefore able to investigate their causal
effects on ACE2 and TMPRSS2 expression in the lung, and ACE levels in the plasma [32]. For ACEi drugs
effects, we used two complementary instrument selection strategies based on associations of variants at the
ACE locus with circulating serum ACE levels and SBP, respectively, and the consistent findings with both
approaches add strength to our conclusions. Our Mendelian randomization approach is better able to
overcome the confounding and reverse causation bias that can limit causal inferences from conventional
epidemiological approaches [29,72]. Considering independent cohorts to assess lung expression of ACE2
and TMPRSS2 [44,45], and plasma levels of ACE2 [51], we were able to explore consistency in our
results, and our conclusions are therefore less vulnerable to false-positive findings.
Our study also has limitations. We only investigated ACE2 and TMPRSS2 expression in the lung and
circulating levels of ACE2 in the plasma, and it may be that expression in other tissues is more relevant
to the risk and severity of COVID-19. Similarly, cellular ACE2 may have very different biological effects
to circulating plasma ACE2. The GWAS analyses for lung ACE2 expression and plasma ACE2 levels
were all performed according to different protocols [44,45,51] and may therefore not be directly
comparable. There was no available genetic instrument for the ARB antihypertensive drug class [35], and
so we were not able to investigate this. The precision of our analyses was also limited, most notably for
the lifetime smoking index results, which had widest confidence intervals. It may therefore be that our
study was not sufficiently powered to exclude a clinically relevant effect for some exposures. The genetic
variants that we used as instrumental variables may have pleiotropic effects where they affect
the outcome through pathways independent of the exposure that they are proxying, and so bias the
consequent Mendelian randomization estimates. While it is not possible to exclude this possibility,
the relatively low heterogeneity detected between Mendelian randomization estimates produced by
different variants, along with the consistency observed when performing analysis methods that are more
robust to pleiotropy, suggests that this is unlikely to be a major source of bias [55]. A further reservation
is the sample size available for genetic associations with the outcome measures, leading to limited power
to detect a causal effect, particularly for the molecular outcomes. Finally, this study was not able to
investigate off-target effects of ACE inhibitors that are unrelated to their intended protein target.
In summary, this Mendelian randomization study does not identify consistent evidence to support
that ACEi antihypertensive drugs or cardiometabolic traits affect lung expression of ACE2 and




9expert consensus guidelines for the management of hypertension in the face of the current COVID-19
pandemic [60]. Efforts should be made by scientists and the news media to ensure that speculative
stories with little evidential support are not propagated [73]. While cardiometabolic risk factors can be
used to stratify patients in terms of their vulnerability to COVID-19, our data do not provide
consistent support that the expression of ACE2 or TMPRSS2 represents causal mechanisms underlying
these associations.
Ethics. The data used in this work are obtained from published studies that obtained relevant participant consent and
ethical approval.
Data accessibility. All variants used as instruments and their genetic association estimates were selected from publicly
available data sources and are provided in electronic supplementary material, Tables S1–S8. GWAS summary data
for all the outcomes considered in this study are publicly available at http://dx.doi.org/10.6084/m9.figshare.
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